- Conditions
- Papulopustular Rosacea
- Interventions
- Azelaic acid foam 15%, Vehicle foam
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Fremont, California • Santa Monica, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1992
of 31,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Sarilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pregnancy, Unplanned, Sexually Transmitted Diseases
- Interventions
- About Us
- Behavioral
- Lead sponsor
- ETR Associates
- Other
- Eligibility
- 14 Years to 18 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Oakland, California • San Diego, California • Scotts Valley, California
- Conditions
- Hemolytic Disease of the Fetus and Newborn
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
- Interventions
- Septal Scoring Along Midline Endocardium
- Device
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cigarette Smoking, Nicotine Vaping
- Interventions
- Promotion factors, Mitigation strategies
- Behavioral
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Fibromyalgia
- Interventions
- Ketotifen, Placebo (Sugar Pill)
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Leptomeningeal Disease
- Interventions
- MRI Scan, VUEWAY, Gadavist
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 11
- States / cities
- Sun City, Arizona • Sherman Oaks, California • Orlando, Florida + 8 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- Metformin, Placebo
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostatic Neoplasms
- Interventions
- Niraparib, Apalutamide, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- West Hollywood, California • Louisville, Kentucky • Portland, Oregon + 1 more
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Lung Cancer
- Interventions
- Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Uncontrolled Hypertension
- Interventions
- Baxdrostat, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Montclair, California + 6 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
- Conditions
- Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Interventions
- Regular blood sample collection for ctDNA assessment
- Procedure
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,079 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- California City, California • Concord, California • Greenbrae, California + 14 more
- Conditions
- Healthy
- Interventions
- LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 32
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Dyspnea, Lactic Acidosis, Muscle, Breathlessness, Exercise, Recovery
- Interventions
- High Velocity Therapy
- Device
- Lead sponsor
- Vapotherm, Inc.
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Acute Compartment Syndrome
- Interventions
- Measurement of the Intra-Compartmental Pressure with the MY01 device
- Device
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Nashville, Tennessee
- Conditions
- Acne
- Interventions
- Spironolactone, Doxycycline Hyclate
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 16 Years to 40 Years · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 18
- States / cities
- Fort Smith, Arkansas • San Francisco, California • Sherman Oaks, California + 13 more
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cachexia
- Interventions
- Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years to 75 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Well-Being, Psychological
- Interventions
- Healthy Minds Program App
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin